Magnetar Financial LLC Acquires New Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Magnetar Financial LLC bought a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 9,125 shares of the company's stock, valued at approximately $359,000.

Several other large investors have also recently bought and sold shares of CRSP. Boston Family Office LLC increased its holdings in shares of CRISPR Therapeutics by 2.2% during the 3rd quarter. Boston Family Office LLC now owns 9,763 shares of the company's stock worth $459,000 after purchasing an additional 213 shares during the period. Bedell Frazier Investment Counselling LLC increased its stake in CRISPR Therapeutics by 0.8% during the third quarter. Bedell Frazier Investment Counselling LLC now owns 26,357 shares of the company's stock valued at $1,238,000 after acquiring an additional 218 shares during the period. The Manufacturers Life Insurance Company raised its holdings in CRISPR Therapeutics by 1.9% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 12,477 shares of the company's stock valued at $586,000 after acquiring an additional 231 shares in the last quarter. Intellectus Partners LLC lifted its position in shares of CRISPR Therapeutics by 3.6% in the 4th quarter. Intellectus Partners LLC now owns 7,131 shares of the company's stock worth $281,000 after acquiring an additional 250 shares during the period. Finally, Farrow Financial Inc. grew its holdings in shares of CRISPR Therapeutics by 1.4% during the 4th quarter. Farrow Financial Inc. now owns 20,097 shares of the company's stock worth $777,000 after purchasing an additional 270 shares in the last quarter. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Analyst Ratings Changes

Several research analysts recently commented on the company. Chardan Capital reduced their target price on CRISPR Therapeutics from $94.00 to $84.00 and set a "buy" rating for the company in a research report on Thursday, February 13th. Cantor Fitzgerald reissued a "neutral" rating on shares of CRISPR Therapeutics in a report on Wednesday, February 19th. Barclays raised their price objective on shares of CRISPR Therapeutics from $55.00 to $56.00 and gave the company an "equal weight" rating in a research report on Wednesday, February 12th. StockNews.com raised CRISPR Therapeutics to a "sell" rating in a research note on Friday, March 21st. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $86.00 target price on shares of CRISPR Therapeutics in a report on Thursday, February 13th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $73.11.

Insider Buying and Selling

In other CRISPR Therapeutics news, Director John Greene purchased 7,000 shares of the firm's stock in a transaction that occurred on Wednesday, February 26th. The shares were acquired at an average cost of $44.85 per share, for a total transaction of $313,950.00. Following the completion of the purchase, the director now owns 7,000 shares of the company's stock, valued at approximately $313,950. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Samarth Kulkarni sold 9,973 shares of the stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $423,054.66. Following the transaction, the chief executive officer now owns 180,890 shares in the company, valued at approximately $7,673,353.80. The trade was a 5.23 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 32,381 shares of company stock worth $1,608,243. Company insiders own 4.10% of the company's stock.

CRISPR Therapeutics Stock Performance

NASDAQ CRSP traded down $1.14 during trading on Thursday, hitting $38.04. The stock had a trading volume of 1,721,703 shares, compared to its average volume of 1,536,390. CRISPR Therapeutics AG has a 12 month low of $36.52 and a 12 month high of $71.54. The company's 50-day moving average price is $43.21 and its two-hundred day moving average price is $45.28. The company has a market capitalization of $3.26 billion, a PE ratio of -8.70 and a beta of 1.77.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. As a group, equities analysts anticipate that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.